HCA Healthcare (NYSE:HCA) Issues FY 2025 Earnings Guidance

HCA Healthcare (NYSE:HCA) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 24.050-25.850 for the period, compared to the consensus EPS estimate of 24.610. The company issued revenue guidance of $72.8 billion-$75.8 billion, compared to the consensus revenue estimate of $74.8 billion.

HCA Healthcare Price Performance

NYSE:HCA opened at $325.18 on Friday. The stock has a market cap of $82.37 billion, a PE ratio of 14.60, a P/E/G ratio of 1.09 and a beta of 1.64. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. The business’s 50-day simple moving average is $314.50 and its two-hundred day simple moving average is $352.84. HCA Healthcare has a 52 week low of $278.68 and a 52 week high of $417.14.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wells Fargo & Company lowered HCA Healthcare from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $400.00 to $320.00 in a research report on Monday, November 25th. Barclays reduced their price objective on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Morgan Stanley dropped their price target on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Truist Financial lowered their price objective on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $380.00 price target on shares of HCA Healthcare in a research report on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $385.27.

Insider Activity at HCA Healthcare

In related news, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares in the company, valued at approximately $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Erol R. Akdamar sold 2,900 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the sale, the insider now owns 6,843 shares in the company, valued at $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.